Title: Method for Diagnosing Acute Lymphomic Leukemia using miR-222
Patent Number: 8,349,560
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The invention comprises “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins,” the patent's abstract states.
Title: Method for Diagnosing Acute Lymphomic Leukemia using miR-125b
Patent Number: 8,349,561
Filed: Oct. 17, 2011
Inventor: Carlo Croce, Ohio State University
The invention comprises “compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins,” the patent's abstract states.
Title: Method for Diagnosing Poor Survival Prognosis Colon Cancer using Let-7g
Patent Number: 8,349,568
Filed: Nov. 14, 2011
Lead Inventor: Carlo Croce, Ohio State University
The invention comprises “novel methods and compositions for the diagnosis and treatment of colon cancers,” the patent's abstract states. “In particular, the ... invention provides diagnostics and prognostics for colon cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.”
Title: Single-Stranded Extended Dicer-Substrate Agents and Methods for the Specific Inhibition of Gene Expression
Patent Number: 8,349,809
Filed: June 25, 2010
Inventor: Bob Brown, Dicerna Pharmaceuticals
“The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double-stranded nucleic acid in an amount effective to reduce expression of a target gene in a cell,” the patent's abstract states. “The dsNAs of the invention possess a single-stranded extension (in most embodiments, the single-stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single-stranded extended Dicer-substrate siRNAs were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.”
Title: Conserved HBV and HCV Sequences Useful for Gene Silencing
Patent Number: 8,350,021
Filed: June 10, 2004
Lead Inventor: Catherine Pachuk, Alnylam Pharmaceuticals (Nucleonics)
The patent, its abstract states, claims “conserved consensus sequences from known hepatitis B virus strains and known hepatitis C virus strains, which are useful in inhibiting the expression of the viruses in mammalian cells. These sequences are useful to silence the genes of HBV and HCV, thereby providing therapeutic utility against HBV and HCV viral infection in humans.”
Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
Application Number: 20130005791
Filed: March 29, 2012
Lead Inventor: Rachel Meyers, Alnylam Pharmaceuticals
The invention, the patent's abstract states, is “based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the … invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject. These findings can be applied to other respiratory viruses.”
Title: Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus
Application Number: 20130005793
Filed: June 28, 2012
Lead Inventor: Daniel Chin, Arrowhead Research
“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a hepatitis B virus gene,” the patent's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by hepatitis B virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a hepatitis B virus gene in a cell.”
Title: Methods and Sequences to Suppress Primate Huntington Gene Expression
Application Number: 20130005794
Filed: Aug. 31, 2012
Lead Inventor: William Kaemmerer, Medtronic
The invention, the patent application's abstract states, comprises “sequences, molecules, and methods used to suppress the expression of [Huntington's disease] genes encoding for huntingtin protein in primates including Macaca mulatto and Homo sapiens. These sequences, molecules, and methods aid in the study of the pathogenesis of [Huntington's disease] and can also provide a treatment for this disease.”
Title: Method for Proliferating Cardiomyocytes using microRNA
Application Number: 20130005796
Filed: March 11, 2011
Lead Inventor: Kayoko Kawashimi, Daiichi Sankyo
The patent, its abstract states, claims “a method for proliferating cardiomyocytes … [using an] miRNA that promotes the proliferation of cardiomyocytes ... a vector for the treatment of heart diseases; and a pharmaceutical composition or the like for the treatment of heart diseases. … The miRNA is preferably one selected from the group consisting of miR-148a, miR-148b, miR-152 and miR-373 that are mature miRNAs, precursors of the aforementioned miRNAs, and mutants and analogues of the miRNAs and the precursors.”